Tumors with hormone receptor-positive subtypes receive endocrine therapy or targeted antibody treatment; however, triple-negative breast cancer is one of the most aggressive types of breast cancer, with a high recurrence rate, making it the most difficult to treat (Palma et al. 2015). This evidence concerns the gene NR4A1 and breast cancer.